By Clinical Research News Staff

July 21, 2026 | Anthropic yesterday announced a focused call for applications for work on rare genetic diseases. Accepted applicants will receive up to $50,000 in Claude credits over six months, with the goal of building a community of researchers looking into how AI can reshape our understanding of rare disease.

Rare disease research is challenging, and Anthropic believes AI can help. “AI makes it possible to accurately model rare genetic diseases and detect patterns across them,” according to the company announcement. “It also helps researchers synthesize findings across a large corpus of literature, quickly extract information from limited datasets, and create shared terminology, all of which informs how researchers can better use the information they do have, even as more work is done to generate more data and address challenges pertaining to access and geography.”

Research grant applicants will be accepted in two “tracks.” The first track aims to foster collaboration between clinical researchers, patient organizations, and data scientists to increase the pace of progress in basic science and the discovery of the mechanisms underlying rare diseases. The second track will support biotechnologists and early-stage biotechs working to accelerate drug development for rare diseases.

Applications will be accepted through August 2, 2026, at 11:59 PM PST. Grantees can use their credits to access Claude Opus or other generally available models approved for use in biology.

Basic Research: Monarch Initiative

Anthropic names the Monarch Initiative, an international consortium working to improve diagnosis and mechanism discovery for patients with rare diseases, as an early partner of the basic research track. Monarch develops standards and resources such as the Mondo Disease Ontology, a computational framework and coding system that reconciles disease definitions scattered across OMIM, Orphanet, ICD, and dozens of other sources; as well as the Monarch Knowledge Graph, which integrates genotype-phenotype data across species to aid diagnostics and mechanism discovery.

Most recently, Monarch contributors have been stitching data and knowledge together in a new agent-friendly mechanistic disease classification library called DisMech, where Claude can read case reports, variant databases, registry schemas, raw public data, and more, and point out mechanistic similarities between diseases at an unmatched pace and scale, the company says.

Monarch invites grantees to use and contribute to its resources, such as Mondo and DisMech, to reveal new mechanistic hypotheses that will support developing treatments. Outputs from this track will be made publicly available at Monarchinitiative.org. The program will be augmented by additional community-building efforts, such as future rare disease hackathons.

“We will continue to partner with Monarch and others to approach this problem from the angles where AI is less obviously applicable, and we’ll share what we learn as we do,” Anthropic writes in the announcement.

Biotech Partnerships: Every Cure

Although many aspects of drug development are difficult to expedite because of manufacturing constraints or safety testing, Anthropic is confident there is room for speed gains. By granting API credits and Claude Science access to the many biotechnologists and startups working in this space, the company hopes to encourage the experiments necessary to explore and identify such solutions.

The company highlights several startups using Claude for drug development. Every Cure, an existing AI for Science grantee, is using Claude to identify drug repurposing opportunities across millions of candidates. The Centre for Population Genomics, a collaboration between the Garvan Institute and the Murdoch Children’s Research Institute, is building a Claude-based system that drafts variant classifications for expert review, one of the biggest bottlenecks in diagnosing rare genetic conditions. And the Violet Research Institute, a small nonprofit researching ultra-rare genetic diseases is using Claude to navigate FDA guidelines, run bioinformatics pipelines, analyze experimental data, draft regulatory filings, and more.